FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to biochemistry and represents a pharmaceutical compound for treating conditions caused by lysosomal acid lipase deficit, containing recovered human recombinant lysosomal acid lipase including SEQ ID NO: 2, and a pharmaceutically acceptable carrier, solvent or excipient, wherein the pharmaceutical compound represents an aqueous solution, which has pH from approximately 5.6 to approximately 6.2, or pH 5.9±0.2, and LAL is N-attached glycolised in position Asn15, Asn80, Asn140, Asn252 and Asn300 of the sequence SEQ ID NO: 2 and contains certain N-linked glycosylation profile.
EFFECT: invention enables producing the effective preparation for treating conditions caused by lysosomal acid lipase deficit.
20 cl, 30 dwg, 6 tbl, 20 ex
| Title | Year | Author | Number |
|---|---|---|---|
| LYSOSOMAL DISEASE ACCUMULATION ENZYME | 2017 |
|
RU2741116C2 |
| PRODUCTION OF HIGH-MANNOSE PROTEINS IN VEGETABLE CULTURES | 2004 |
|
RU2385928C2 |
| USING ACID LYSOSOME LIPASE FOR TREATING ACID LYSOSOME LIPASE DEFICIENCY IN PATIENTS | 2011 |
|
RU2550961C2 |
| PRODUCTION OF HIGH-MANNOSE PROTEINS IN PLANT CULTURES | 2009 |
|
RU2535342C2 |
| LIVER-SPECIFIC STRUCTURES, EXPRESSION CASSETTES OF FACTOR VIII AND THEIR APPLICATION METHODS | 2016 |
|
RU2774874C2 |
| MODIFIED CLOSED CIRCULAR DNA (CCDNA) CONTAINING SYMMETRIC MODIFIED INVERTED END REPEATED SEQUENCES | 2019 |
|
RU2816963C2 |
| COMPOSITIONS AND METHODS FOR INCREASING THE STABILITY OF TRANSGENES IN POXVIRUSES | 2017 |
|
RU2756534C2 |
| COMPOSITIONS OF NON-VIRAL NON-CAPSID DNA VECTORS BASED ON LIPID NANOPARTICLES | 2018 |
|
RU2778407C2 |
| TRANSGENIC PLANTS WITH ENHANCED GROWTH CHARACTERISTICS | 2009 |
|
RU2582260C2 |
| MODIFIED SULPHAMIDASE AND METHOD FOR PRODUCTION THEREOF | 2015 |
|
RU2708026C2 |
